Business, energy, technology, markets and global industry news from Business News Today

cholesterol therapy

PharmaDeviceNews cholesterol therapy
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More